PRRX1 and neoplasm: Of note, PRRX1 was amplified in ~ 10% (n = 36) of TCGA HCC tumour samples, but this amplification did not strikingly overlap with known mutated genes in HCC, i.e. TP53 or CTNNB1 (Fig. S1C).